02.06.2013 Views

Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

(2002): Caplehorn JR+, Aust N Z J Public Health 26(4), 358<br />

(2002): Ernst E+, Aust N Z J Public Health 26(4), 364<br />

(2002): Mikolaenko I+, Am J Forensic Med Pathol 23(3), 299 (101<br />

cases)<br />

(2001): Vormfelde SV+, Pharmacopsychiatry 34(6), 217<br />

Injection-site burning<br />

Injection-site induration<br />

Injection-site pain (1–10%)<br />

Rhabdomyolysis<br />

(1990): Larpin R+, Presse Med 19(30), 1403<br />

(1983): Nanji AA+, J Toxicol Clin Toxicol 20(4), 353<br />

METHAMPHETAMINE<br />

Trade name: Desoxyn (Ovation)<br />

Indications: Attention deficit disorder, obesity<br />

Category: Amphetamine<br />

Half-life: 4–5 hours<br />

Clinically important, potentially hazardous interactions<br />

with: fluoxetine, fluvoxamine, MAO inhibitors, paroxetine,<br />

phenelzine, sertraline, tranylcypromine<br />

Reactions<br />

Skin<br />

Acaraphobia<br />

Diaphoresis (1–10%)<br />

Lichenoid eruption<br />

(1994): Deloach-Banta LJ, Cutis 53, 97<br />

Nodular eruption<br />

(2002): Patatanian E+, Pharmacotherapy 22(9), 1157 (27 cases)<br />

Pigmentation<br />

Rash (sic) (

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!